Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007
Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
You may also be interested in...
Situations look bleak for medical device IPOs interested in going public, but venture investors in companies that went public last year are beginning to sell or divest some of their shares.
Venture capital is flowing to later-stage companies as VCs prepare to carry their companies along farther than they have in the past.
Intuitive Surgical is the closest thing the health care industry has to Google Inc. With shares trading at or around $300 at publishing time, the robotic surgery pioneer clearly leads the field in a review of five-year and one-year stock valuations of publicly-traded medical device companies conducted by IN VIVO. According to this survey, over the past five years, public investors have shown a strong level of support for the stock of companies with a laser-like focus on a single market area.